Thirteen healthy volunteers participating in an open and randomized study received two single doses (25 and 50 rag) of codeine orally two weeks apart. Urine concentrations of opiates were studied for 96 h, and plasma concentrations of codeine and the metabolites codeine-6-glucuronide (C6G), morphine, morphine-3-glucuronide (M3G), and morphine-6-glucuronide (M6G) were monitored for 24 h. Plasma was analyzed by highperformance liquid chromatography. Measurements of urine were made with the EMIT opiate-screening assay and with gas chromatography-mass spectrometry for total (conjugates liberated by acid hydrolysis) codeine, morphine, and norcodeine. In urine, the ratio between total recovered morphine and codeine as expressed in percent ranged from 2.3 to 23.3% with a mean value of 9.8%. This ratio increased with time, and, in all but three subjects, rose to greater than 1 after 22-36 h. In 58% of cases, this occurred within the detection time in the EMIT assay. The detection time in the EMIT screening assay was found to be 20-39 h after the 25-rag dose and 30-52 h after the 50-rag dose. Elimination rates calculated from urine data corrected for creatinine concentration showed that morphine was eliminated more slowly than codeine. In plasma, the highest concentrations and area-under-curve values were observed for C6G, followed by codeine and M3G. All compounds had peak plasma values 1-2 h after dosing. The elimination of M3G was slower than that of C6G. We concluded that the relative proportion of codeine and morphine varies both between individuals and as a function of time and that morphine may be present in concentrations above those of codeine even after moderate and single doses of codeine. This must be taken into consideration when interpreting the presence of opiates during drugs-of-abuse testing.
Introduction
Drugs-of-abuse testing in urine is a delicate matter that requires analytical, medical, and legal expertise. According to established standards, the laboratory procedure is performed in "Author to whom correspondence should be addressed.
two parts (1) . After initial screening of urine with immunoassay for classes of drugs, the positive findings are confirmed by gas chromatographic-mass spectrometric (GC-MS) procedures (1) . Different cutoff values, or detection limits, may be used in these two analytical steps. For opiates, the Department of Human and Health Services mandates 300 ng/mL of opiate in the screening and 300 ng/mL each of codeine and morphine in the confirmation (1) . However, even after confirmation by GC-MS, results may be difficult to interpret because both morphine and codeine can be found in urine without the subject having consumed illicit drugs (2) . The reason for this confusing situation is found in the metabolism of the involved drugs: both heroin and codeine are metabolically converted to morphine. In an early study with a radiotracer technique, about 10% of oral codeine intake was found to be converted metabolically to morphine (3) . However, more recent studies indicate that the activity in the codeine--Odemethylation pathway is partly determined by genetics, giving rise to a range of phenotypes with variable relative proportion of morphine formation (4, 5) . Although the existence of slow and extensive metabolizers, according to enzyme capacity in O-demethylation of codeine, has been demonstrated (5-7), its impact on the interpretation in drugs-of-abuse testing remains to be established. There are a number of pharmacokinetic studies on codeine (7) (8) (9) (10) (11) (12) , but only a few have specifically considered the important aspects of drugs-of-abuse testing (11, 12) . It is clear from previous studies that the terminal elimination rates of morphine and its glucuronide conjugate from plasma are slower than those of codeine and its 6-glucuronide conjugate (7) . This may cause the ratio of morphine to codeine in urine to change over time. In addition, we recently pointed out a possible analytical pitfall in the hydrolysis of the predominating urine conjugates of codeine and morphine (13) . An incorrect determination of the proportion of total morphine and codeine in urine may result if hydrolysis is incorrectly performed.
We conducted this study in order to evaluate codeine metabolism with special emphasis on issues of relevance for opiate drugs-of-abuse testing. The study involved thirteen healthy volunteers consuming single doses of codeine in two different amounts. Codeine and its metabolites in both plasma and urine were carefully measured for accuracy.
Materials and Methods

Chemicals
Codeine phosphate and morphine hydrochloride were obtained from Apoteksbolaget AB (Stockholm, Sweden); rnorphine-3-glucuronide, morphine-6-glucuronide, and nalorphine were from Sigma Chemical Co. (St. Louis, MO); and N-methyl-N-trimethylsilyltrifluoroacetamide (MSTFA) was from Fluka Chemie AG (Buchs, Switzerland). Codeine-6-glucuronide was supplied by J.O. Svensson (Huddinge Hospital, Stockholm, Sweden). All other chemicals used were of analytical grade or HPLC grade and were obtained from commercial sources.
Clinical experiment
Thirteen healthy volunteers with no history of drug abuse were recruited (Table I) . They received two different oral codeine doses, 25 and 50 rag, in an open and randomized design with a 2-week wash-out period in between doses. The codeine dose was administered at approximately 9 a.m. after an overnight fast. Before administration of the codeine, blood and urine samples were collected. Further blood samples were then taken at 0.5, 1, 2, 4, 6, 7, and 24 h after dosing. Blood was collected by venous puncture and drawn into heparinized vacutainer tubes. Plasma was prepared by centrifugation within 30 rain and stored at -70~ Urine was collected for 96 h after dosing in plastic vessels, and a 10-mL sample was stored (-70~ from each void. During the first 12 h, all urine was stored in 4-h pools. The study was approved by the Ethics Committee at the Karolinska Hospital.
Plasma and urine analyses
Screening assay of urine for opiates was performed using EMIT reagents (Syva Co., Palo Alto, CA) on a Monarch 2000 Chemistry System (Instrumentation Laboratory, Lexington, MA). Measurement of urinary creatinine concentrations was also performed on the Monarch 2000 Chemistry System using reagents based on the Jaff~ reaction.
Target analysis of total codeine, morphine, and norcodeine in urine was performed using capillary column electron capture GC (Shimadzu GC-9AM, Shimadzu Corp., Kyoto, Japan) and GC-MS (Finnigan ITS 40 WITNESS system, Finnigan MAT, San Jose, CA) (13) . The sample preparation involved acid hydrolysis of urine, solid-phase extraction, and formation of trimethylsilyl derivatives (13) . The lower limit of quantitation was 0.1 IJmol/L for all three compounds. Measurement of plasma concentrations of codeine, codeine-6-glucuronide (C6G), morphine, morphine-3-glucuronide (M3G), and morphine-6-glucuronide (M6G) was performed using a high-performance liquid chromatographic (HPLC) method with ultraviolet and electrochemical detection (5, 14) . The sample preparation was done with solid-phase extraction using SEP-PAK Light cartridges. Limits of quantitation were as follows: codeine, 15 nmol/L; C6G, 10 nmol/L; morphine, 0.6 nmol/L; M3G, 4.0 nmol/L; M6G, 0.4 nmol/L.
Pharmacokinetic parameters derived from concentrationtime data in all subjects were calculated using Siphar software (Simed, Crgteil, France) (15, 16) . Parameters derived from Siphar made up the area under the plasma concentration curve from 0 to 7 h (AUC0_7) and elimination half-life (h/2). AUC0_7 was calculated using the linear trapezoidal rule. Maximum concentration (Cmax) and the time when it occured (Tmax) were taken from observed experimental values. Statistical calculations were done using StatView software (Abacus Concepts, Berkeley, CA) on Macintosh computers.
Results
Urine data
The mean values of totally recovered codeine in urine from the time of dose intake until the point of the last positive screening result were 66 and 57% of the given dose at the high and low dose levels, respectively (Table II) . There was a predominance of codeine over morphine and norcodeine in all individuals. The ratios between total recovered morphine and codeine ranged from 2.3 to 23.3% with a mean value of 9.8%. There was a high degree of intra-individual concordance in morphine-codeine ratios between the two doses (r 2 = 0.94). Morphine concentrations were higher than norcodeine concentrations in 7 out of 10 subjects. The mean detection times in the EMIT opiate screening assay were 29.7 and 40.4 h after 25 and 50 mg codeine, respectively (Table III) . For one subject, the detection time was longer after the low dose. In 10 of the 13 subjects, the morphine concentration became higher than codeine (morphine-codeine >1) at some point during the excretion phase. In 58% of the cases, this occurred within the detection time of the EMIT assay, and the time appeared independent of dose (29.9 h after 25 mg and 28.9 h after 50 rag). In three subjects (3, 8, and 13) , there was more codeine at all time points and at both doses ( Table IIl) .
The urinary elimination rates were determined from concentrations corrected for creatinine (Table IV) . This showed that morphine had a slower excretion rate (longer tl/2) than codeine in all individuals. The calculated elimination rates were similar for the two doses.
A graphic illustration of codeine and morphine excretion in urine is shown in Figure 1 . The graph was prepared by fitting all data from the 50-rag dose to a three exponential model. The elimination follows a biphasic curve for both compounds. In another graph (Figure 2) , the morphine to codeine ratio is plotted as a function of the total codeine, morphine, and norcodeine concentrations as measured by GC-MS. The morphine to codeine ratio increases when the concentrations of codeine and metabolites approach the cutoff limit of screening assays. The graph also includes results from samples with negative results in the EMIT screening assay. The highest observed morphine-codeine ratio in a sample with a positive outcome in the EMIT screening assay was 3.
Plasma data
Plasma pharmacokinetic parameters were determined for codeine, C6G/M3G, morphine, and M6G (Table V) . The peak concentrations (Tmax) of codeine, morphine, and corresponding glucuronides occurred at about the same point in time (1-2 h) . The highest peak concentrations and area-under-curve (AUC) values were observed for C6G-M3G concentrations were higher than morphine and the M6G with an AUC ratio of M3G-morphine plus M6G of about 5 at both dose levels 9 The elimination rate (tw21~) of morphine was slower than for codeine 9 This was also true for the corresponding glucuronides (Table V) .
In Figure 3 , the plasma concentrations of codeine and metabolites over time for the 50-rag dose are plotted after fitting pooled data from all 13 subjects to a pharmacokinetic three-exponential model. C6G dominated quantitatively at all time points, but M3G became more dominant at 24 h after dosing 9
Correlation between plasma and urine data
There was a significant correlation (p< 0.001, r 2 = 0.84) between individual urine concentration (4-8 h) of morphine and plasma (6 h) concentration of M3G using data from both doses. Similarly, a corresponding significant (p < 0.001, r 2 = 0.27) correlation, although weaker, was observed for urine (4-8 h) codeine and plasma (6 h) C6G.
In another data analysis, the relation between the morphine to codeine urine ratio and the ratio between sum of plasma AUC0_7 for (morphine + M3G + M6G) and (codeine + C6G) were evaluated 9 There was a significant (p < 0 9 r 2 = 0.63) correlation between the two measures with a higher ratio (1.7 times) measured in urine. 
D i s c u s s i o n
The present study of codeine metabolism in healthy volunteers confirms that the rate of morphine formation is variable between individuals and documents in detail how the morphine-codeine ratio in urine changes over time after intake 9 Two main factors determine the actual morphine-codeine ratio after codeine intake in an individual at the time of sample collection. First, the interindividual variability in rate of morphine formation is related to the individual's hepatic drug metabolizing capacity, which is determined by individual phenotype. Second, the time-dependent change in morphine to codeine ratio is related to differences in pharmacokinetics between morphine and codeine and their respective glucuronide conjugates.
There is a genetic polymorphism in the liver membrane enzyme system (CYP2D6) responsible for the O-demethylation of codeine which forms morphine 9 Individuals with both decreased and increased activity are known to exist (4, 5, 7) . The present study revealed that both the absolute and relative recovery of codeine and morphine were variable between individuals. Subjects 3, 8, and 13 had a low relative rate of forma-._.9. Codeine and metabolites (pmoles/L) Figure   2 . The urinary ratio of morphine to codeine as a function of total codeine metabolite concentration. Data from both 25-and 50-mg doses from all 13 individuals are presented. Samples negative in the EMIT screening assay but with detectable morphine and codeine concentrations in the verification assay are also included. The highest morphine-codeine value in an EMIT positive sample was 3. A presents all data, and B presents only samples with low concentrations (i.e., < 30 pmol/L). tion of morphine (Table II) , and none of these individuals reached a morphine--codeine ratio of greater than 1 at any time during the elimination (Table III) . These three individuals also showed relatively low plasma levels of morphine and glucuronides, which indicated that they were poor metabolizers. The relationship of codeine O-demethylation capacity and the phenotype classification of subjects as poor and extensive metabolizers in the CYP2D6 system has been clearly shown (7) . The frequency of poor metabolizers among our subjects (3/13 = 23%) was somewhat higher than in the general population (17) . The range of total recovered urinary morphine to codeine in our subjects (2.3-23.3%) was in good accordance with previous studies. Cone and co-workers (12) found a range from 2.6 to 30% in 4 subjects, whereas Dutt and co-workers (11) found 3.3 to 17% in 10 subjects. However, the lower rate of morphine formation observed by Vree and Verwey-van Wissen (10), 0 to 8.4%, could be explained by an incomplete hydrolysis by the enzymatic hydrolysis procedure used (13) .
The other factor that contributes to difficulties in distinguishing a codeine intake from other types of opiate intakes by urinalysis is the difference in elimination rate between codeine and its metabolites. The urine and plasma terminal elimination rates showed that morphine is cleared from the body more slowly than codeine (Tables IV and V) . The significant correlation between plasma (6 h) concentrations of M3G and C6G and urine (4-8 h) total morphine and codeine concentrations indicates that the most important factor contributing to the declining codeine-morphine ratio is the difference in the elimination rates of the major urinary metabolites, M3G and C6G. There is a more than twofold difference between M3G and C6G in plasma tlrz values (Table V) . This is graphically illustrated in Figure 3 . In addition, the elimination rates calculated for urine are in accordance with plasma terminal elimination rates for M3G and C6G.
Various criteria have been proposed for the interpretation of analytical results in order to distinguish codeine from other opiates. It is clear that the sole presence of codeine is not firm proof of a pure codeine intake and this was noted already by Solomon in 1974 (18) . In addition, ingestion of poppy seeds, intake of impure heroin, or mixed opiate intake might be causes of codeine presence and must be considered. The criteria suggested by EISohly (2) that codeine greater than 300 ng/mL and a morphine to codeine ratio less than 2 indicate pure codeine intake fits well with our data. Our data even suggest that it can be modified to simply a positive screening outcome and a morphine to codeine ratio less than 3. Similarly, the criteria for codeine intake suggested by Dutt and co-workers (11), the presence of codeine with less than 200 ng/mL morphine or a morphine to codeine ratio of less than 2 with more than 200 ng/mL morphine, fit well with our results ifa somewhat higher limit for the morphine to codeine ratio is applied (i.e., 3). At trace concentrations, an even higher morphine to codeine ratio can occur, as we found a maximal ratio of 6 in samples that were negative in the screening when both morphine and codeine could be quantitated in the verification assay. However, it must be noted that the first criterion (i.e., presence of codeine with low morphine concentration) suggested by Dutt and co-workers (11) may not conclusively distinguish other opiate intakes from a poppy seed intake. At higher.concentrations, however, another criterion could be set up for the morphine to codeine ratio. From our results, we suggest that at codeine concentrations greater than 5000 ng/mL, a morphine to codeine ratio greater than 2 can be considered as firm evidence of pure codeine intake. The detection time by the EMIT screening assay of the single dose intake ranged from 20 to 52 h. The higher dose (50 rag) gave significantly longer detection time (Table III) . The difference in mean values between doses was somewhat greater than the urinary elimination half-lives of codeine and morphine. One factor that greatly influences detection time is urine dilution. The use of urine-creatinine measurements in drugs-ofabuse testing has been discussed as a marker for urine dilution, where low values indicate an increased risk of false negative results (19) . Correction of cannabinoid levels with creatinine concentration can be used in the evaluation of patients adherence to abstinence from cannabis abuse (20) . In the present study, the urine concentrations of codeine and morphine were succesfully corrected with creatinine ( Figure 1) . Measurement of creatinine in urine may also be useful in opiate testing to reveal individuals who screen positive for a prolonged period of time after only minor intake of codeine. Further research is necessary to evaluate this possibility.
Conclusion
As we have previously shown, the liberation of morphine and codeine from their glucuronidated forms is an essential requirement in confirmation assay (13) . A poor hydrolysis may result in misleading low levels of codeine and morphine and misjudgment in the interpretation of the final result. For this reason, the efficacy of the hydrolysis of the used confirmation method must also be taken into consideration when the interpretations of the positive findings are made.
We have found that morphine may be present in concentrations above those of codeine even after intake of only codeine in small doses. This should be considered when interpreting a confirmed-positive opiate finding.
